Pike Therapeutics
Pike Therapeutics is dedicated to transforming dronabinol to change the lives of people and families suffering from Parkinson's and Alzheimer's. They focus on developing a unique platform with proprietary continuous delivery technology aimed at improving safety, efficacy, and patient outcomes, especially targeting non-motor symptoms in Parkinson’s Disease and agitation in Alzheimer’s and dementia. Their approach reduces drug exposure, minimizes adverse effects, and offers convenience through less frequent dosing. The company has a strategic partnership with Transdermal Research Pharm Laboratories LLC and is a spin-out of Starton Therapeutics Inc.
Industries
Nr. of Employees
small (1-50)
Pike Therapeutics
Pike Therapeutics USA, Inc. Corporation Trust Center 1209 Orange Street Wilmington, Delaware 19801 County of New Castle USA
Patents
Products
Multi-day continuous transdermal CBD patch (development candidate)
A transdermal matrix patch designed to deliver synthetic cannabidiol continuously for multiple days to address neurological symptom targets.
Multi-day continuous transdermal dronabinol patch (development candidate)
A transdermal matrix patch formulation containing dronabinol intended for sustained multi-day delivery, targeting neurological indications with potential to follow a reference-based regulatory pathway.
Multi-day continuous transdermal CBD patch (development candidate)
A transdermal matrix patch designed to deliver synthetic cannabidiol continuously for multiple days to address neurological symptom targets.
Multi-day continuous transdermal dronabinol patch (development candidate)
A transdermal matrix patch formulation containing dronabinol intended for sustained multi-day delivery, targeting neurological indications with potential to follow a reference-based regulatory pathway.
Services
Development of sustained-release transdermal matrix patches for cannabinoids and dronabinol, including formulation optimization and preclinical evaluation.
Execution and analysis of animal pharmacokinetic studies to evaluate systemic exposure and delivery profile of transdermal candidates.
Regulatory planning that includes assessment of accelerated or reference-based approval pathways and preparation for regulatory submissions.
Development of sustained-release transdermal matrix patches for cannabinoids and dronabinol, including formulation optimization and preclinical evaluation.
Execution and analysis of animal pharmacokinetic studies to evaluate systemic exposure and delivery profile of transdermal candidates.
Regulatory planning that includes assessment of accelerated or reference-based approval pathways and preparation for regulatory submissions.
Expertise Areas
- Transdermal drug delivery
- Cannabinoid and dronabinol formulation
- Clinical trial design and management
- Regulatory strategy and submissions (including 505(b)(2))
Key Technologies
- Continuous multi-day transdermal drug delivery
- Transdermal matrix patch technology
- Cannabinoid (CBD) formulation
- Dronabinol (THC) formulation
News & Updates
Press release dated 17 June 2022 about positive study results and benefits of their CBD transdermal technology.
Industry news from 22 March 2021 about FDA warning letters to companies selling unapproved CBD products.
Industry news from 21 January 2020 about a study showing CBD's effect on reducing anxiety and tremors in Parkinson’s patients.
Press release dated 17 June 2022 about positive study results and benefits of their CBD transdermal technology.
Industry news from 22 March 2021 about FDA warning letters to companies selling unapproved CBD products.
Industry news from 21 January 2020 about a study showing CBD's effect on reducing anxiety and tremors in Parkinson’s patients.